DeepMed Research

Merck, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: $295.3B

Website: http://www.merck.ph

Clinical Trials

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Phase 3

Recruiting

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer

Interventions: Biological: Sacituzumab tirumotecan
Biological: Bevacizumab
Drug: H1 receptor antagonist
Drug: H2 receptor antagonist
Drug: Acetaminophen (or equivalent)
Drug: Dexamethasone (or equivalent)
Drug: Steroid mouthwash (dexamethasone or equivalent)

First Posted Date: 2025-02-13

Last Posted Date: 2025-05-29

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 770

Registration Number: NCT06824467

Locations: 🇦🇺
Gallipoli Medical Research Ltd ( Site 0214), Brisbane, Queensland, Australia
🇯🇵
Saitama Medical University International Medical Center ( Site 1632), Hidaka, Saitama, Japan
🇯🇵
Niigata Cancer Center Hospital ( Site 1633), Niigata, Japan

and more 23 locations

A Single Dose Study of MK-6194 in Healthy Chinese Participants (MK-6194-014)

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: MK-6194
Biological: Placebo

First Posted Date: 2025-02-12

Last Posted Date: 2025-02-12

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 37

Registration Number: NCT06821334

Locations: 🇨🇳
Peking University Third Hospital (Site 0001), Beijing, Beijing, China

A Study of the Effect of Multiple Doses of Diltiazem on the Plasma Levels of MK-6916 in Healthy Participants (MK-6916-005)

Phase 1

Active, not recruiting

Conditions: Healthy

Interventions: Drug: MK-6916
Drug: Diltiazem

First Posted Date: 2025-02-11

Last Posted Date: 2025-05-15

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 30

Registration Number: NCT06818968

Locations: 🇺🇸
Fortrea CRU, Madison ( Site 0001), Madison, Wisconsin, United States

A Clinical Study of MK-4482 in Chinese Healthy Male Participants (MK-4482-009)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: MK-4482

First Posted Date: 2025-02-10

Last Posted Date: 2025-02-10

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 16

Registration Number: NCT06816030

Locations: 🇨🇳
Peking University Third Hospital (Site 0001), Beijing, Beijing, China

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

Phase 1

Recruiting

Conditions: Malignant Neoplasm
Advanced Solid Tumors

Interventions: Biological: MK-3120

First Posted Date: 2025-02-10

Last Posted Date: 2025-05-25

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 180

Registration Number: NCT06818643

Locations: 🇨🇳
National Taiwan University Hospital ( Site 0160), Taipei, Taiwan
🇨🇳
Peking University First Hospital ( Site 0180), Beijing, Beijing, China
🇰🇷
Asan Medical Center ( Site 0153), Seoul, Korea, Republic of

and more 7 locations

A Study of Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) and MK-8527 in Healthy Participants

Phase 1

Active, not recruiting

Conditions: Healthy

Interventions: Drug: MK-8527
Drug: FTC/TDF

First Posted Date: 2025-02-10

Last Posted Date: 2025-03-19

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 20

Registration Number: NCT06816043

Locations: 🇺🇸
Celerion ( Site 0001), Lincoln, Nebraska, United States

A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)

Phase 1

Recruiting

Conditions: Kidney Failure, Chronic
End-Stage Kidney Disease
Renal Failure, Chronic
Renal Failure, End-Stage
Healthy Participants

Interventions: Drug: MK-5684
Drug: Prednisone
Drug: Fludrocortisone acetate

First Posted Date: 2025-02-07

Last Posted Date: 2025-05-12

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 24

Registration Number: NCT06814132

Locations: 🇺🇸
Orlando Clinical Research Center ( Site 0002), Orlando, Florida, United States
🇺🇸
Research by Design ( Site 0001), Chicago, Illinois, United States

Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)

Phase 2

Recruiting

Conditions: Hypertension, Pulmonary

Interventions: Biological: Sotatercept

First Posted Date: 2025-02-07

Last Posted Date: 2025-05-01

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 130

Registration Number: NCT06814145

Locations: 🇺🇸
Pulmonary Associates, PA ( Site 1008), Phoenix, Arizona, United States

A Single- and Multiple-Dose Study of Enlicitide Chloride (MK-0616) in Healthy Chinese Adult Participants (MK 0616-010)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Enlicitide Chloride
Drug: Placebo

First Posted Date: 2025-02-07

Last Posted Date: 2025-02-07

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 37

Registration Number: NCT06814106

Locations: 🇨🇳
Zhongshan Hospital,Fudan University-Dep. of Clinical Pharmacology (Site 0001), Shanghai, Shanghai, China

A Clinical Study of MK-1084 in Participants With Renal Impairment (MK-1084-010)

Phase 1

Recruiting

Conditions: Healthy
Renal Impairment

Interventions: Drug: MK-1084

First Posted Date: 2025-02-07

Last Posted Date: 2025-04-24

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 30

Registration Number: NCT06814119

Locations: 🇺🇸
Orlando Clinical Research Center ( Site 0002), Orlando, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy